Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,466 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.
Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, Chiari R, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficorella C, Tiseo M. Cortellini A, et al. Among authors: marchetti p. Clin Transl Oncol. 2020 Jun;22(6):844-851. doi: 10.1007/s12094-019-02193-w. Epub 2019 Aug 7. Clin Transl Oncol. 2020. PMID: 31392645
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification.
Mazzotta M, Filetti M, Rossi A, Roberto M, Occhipinti M, Pernazza A, Di Napoli A, Scarpino S, Vecchione A, Giusti R, Marchetti P. Mazzotta M, et al. Among authors: marchetti p. Ann Oncol. 2020 Mar;31(3):440-441. doi: 10.1016/j.annonc.2019.11.016. Epub 2019 Dec 9. Ann Oncol. 2020. PMID: 32067689 Free article. No abstract available.
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
Morelli MF, Santomaggio A, Ricevuto E, Cannita K, De Galitiis F, Tudini M, Bruera G, Mancini M, Pelliccione M, Calista F, Guglielmi F, Martella F, Lanfiuti Baldi P, Porzio G, Russo A, Gebbia N, Iacobelli S, Marchetti P, Ficorella C. Morelli MF, et al. Among authors: marchetti p. Oncol Rep. 2010 Jun;23(6):1635-40. doi: 10.3892/or_00000805. Oncol Rep. 2010. PMID: 20428819 Free article. Clinical Trial.
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D, Mazzotta M, Scalera S, Terrenato I, Sperati F, D'Ambrosio L, Pallocca M, Corleone G, Krasniqi E, Pizzuti L, Barba M, Carpano S, Vici P, Filetti M, Giusti R, Vecchione A, Occhipinti M, Gelibter A, Botticelli A, De Nicola F, Ciuffreda L, Goeman F, Gallo E, Visca P, Pescarmona E, Fanciulli M, De Maria R, Marchetti P, Ciliberto G, Maugeri-Saccà M. Marinelli D, et al. Among authors: marchetti p. Ann Oncol. 2020 Dec;31(12):1746-1754. doi: 10.1016/j.annonc.2020.08.2105. Epub 2020 Aug 28. Ann Oncol. 2020. PMID: 32866624 Free article.
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study.
Cazzaniga ME, Pinotti G, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Fiorentini G, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Melegari E, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V; VICTOR Study Group. Cazzaniga ME, et al. Among authors: marchetti p. Breast. 2019 Dec;48:7-16. doi: 10.1016/j.breast.2019.07.006. Epub 2019 Aug 22. Breast. 2019. PMID: 31470257
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
Cazzaniga ME, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Baldelli A, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Sarti S, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Di Mauro P, Cogliati V, Capici S, Clivio L, Torri V; VICTOR Study Group. Cazzaniga ME, et al. Among authors: marchetti p. Breast Cancer Res Treat. 2021 Dec;190(3):415-424. doi: 10.1007/s10549-021-06375-5. Epub 2021 Sep 21. Breast Cancer Res Treat. 2021. PMID: 34546500 Free PMC article.
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies.
Vici P, Pizzuti L, Mariani L, Zampa G, Santini D, Di Lauro L, Gamucci T, Natoli C, Marchetti P, Barba M, Maugeri-Saccà M, Sergi D, Tomao F, Vizza E, Di Filippo S, Paolini F, Curzio G, Corrado G, Michelotti A, Sanguineti G, Giordano A, De Maria R, Venuti A. Vici P, et al. Among authors: marchetti p. Expert Rev Vaccines. 2016 Oct;15(10):1327-36. doi: 10.1080/14760584.2016.1176533. Epub 2016 May 9. Expert Rev Vaccines. 2016. PMID: 27063030 Free PMC article. Review.
Clinical Predictors of Response to Anti-PD-1 First-Line Treatment in a Single-Centre Patient Cohort: A Real-World Study.
Di Pietro FR, Verkhovskaia S, Mastroeni S, Carbone ML, Abeni D, Di Rocco CZ, Samà N, Zappalà AR, Marchetti P, De Galitiis F, Failla CM, Fortes C. Di Pietro FR, et al. Among authors: marchetti p. Clin Oncol (R Coll Radiol). 2022 Jan;34(1):e18-e24. doi: 10.1016/j.clon.2021.09.006. Epub 2021 Sep 23. Clin Oncol (R Coll Radiol). 2022. PMID: 34563446
1,466 results